Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 3/20 | 0.52 |
| ▸ | SKP1 | P63208 | 3/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.47 |
| ▸ | SMO | Q99835 | 6/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9968433 | 0.91 | SMO (0.52) | CKS1BSKP1SKP2OPRM1OPRD1 | |
| SCHEMBL1533932 | 0.89 | SMO (0.43) | CKS1BSKP1SKP2SMO | |
| SCHEMBL9932747 | 0.88 | SMO (0.51) | CKS1BSKP1SKP2OPRM1OPRD1 | |
| SCHEMBL12841340 | 0.87 | AOC3 (0.44) | CKS1BSKP1SKP2SMO | |
| SCHEMBL9932565 | 0.86 | SMO (0.41) | CKS1BSKP1SKP2SMO | |
| SCHEMBL9932426 | 0.84 | FASN (0.49) | CKS1BSKP1SKP2SMO | |
| SCHEMBL9932527 | 0.84 | CKS1B (0.48) | CKS1BSKP1SKP2OPRM1OPRD1 | |
| SCHEMBL3806273 | 0.83 | OPRM1 (0.54) | CKS1BSKP1SKP2OPRM1OPRD1 | |
| SCHEMBL9968331 | 0.81 | SMO (0.64) | SMO | |
| SCHEMBL9968432 | 0.81 | SMO (0.56) | OPRM1OPRD1OPRK1OGFRL1SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027249-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | CKS1B 187/4885SKP1 720/4885SKP2 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.